Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DTIL stock, giving a Buy rating today.Stay Ahead of the ...

Is it just market speculation, or is there something more significant unfolding behind the scenes? At the core of Precision BioSciences’ sudden stock surge is the company’s gene-editing technology, ...

In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research ...

Gilead Sciences has forged closer ties to its cancer drug partner Arcus Biosciences , although a licensing deal doesn't go as far as the takeover that some market commentators have been predicting.

Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Investing.com -- Shares of Precision BioSciences, Inc. (NASDAQ: DTIL) soared 60% following the announcement of a complete clinical response in the first infant dosed in a Phase 1/2 clinical trial. The ...

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase II for Metastatic Colorectal Cancer.